AGEN:NSD-Agenus Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.91

Change

-0.13 (-4.28)%

Market Cap

USD 0.07B

Volume

0.78M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.61 (-1.07%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-19.89 (-3.63%)

USD 65.38B
ARGX argenx NV ADR

-19.47 (-3.42%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-7.20 (-2.79%)

USD 30.51B
SMMT Summit Therapeutics PLC

-0.69 (-2.80%)

USD 27.07B
ONC BeiGene, Ltd.

-3.95 (-1.67%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.05 (+0.15%)

USD 18.40B
INSM Insmed Inc

-0.55 (-0.84%)

USD 12.52B
INCY Incyte Corporation

-0.75 (-1.26%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

-0.96 (-1.60%)

USD 11.50B

ETFs Containing AGEN

USPY:XETRA L&G Cyber Security UCITS .. 4.81 % 0.00 %

-0.05 (-1.61%)

N/A
BUG Global X Cybersecurity ET.. 4.78 % 0.00 %

-0.55 (-1.61%)

USD 0.99B
FPXE First Trust IPOX Europe E.. 4.44 % 0.00 %

+0.05 (+-1.61%)

USD 3.72M
FPXI First Trust International.. 3.83 % 0.70 %

+0.23 (+-1.61%)

USD 0.14B
ZLU-U:CA BMO Low Volatility US Equ.. 1.97 % 0.00 %

-0.30 (-1.61%)

N/A
ZLU:CA BMO Low Volatility US Equ.. 1.97 % 0.33 %

-0.18 (-1.61%)

CAD 2.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.20% 81% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.20% 81% B- 79% B-
Trailing 12 Months  
Capital Gain -72.26% 28% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.26% 28% F 11% F
Trailing 5 Years  
Capital Gain -94.25% 29% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -94.25% 29% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain 44.85% 79% B- 88% B+
Dividend Return 44.85% 79% B- 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 478.23% 15% F 6% D-
Risk Adjusted Return 9.38% 62% D 45% F
Market Capitalization 0.07B 44% F 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector